Replies to post #13019 on GTC Biotherapeutics (fka GTCB)

[moustifouette]

Hi all, this is my first post. Please forgive me if this has been covered. Does anyone have any sales figures from Leo for atryn in Europe? It's been two years since they got there hands on the product. It would seem that they should be showing some type of sales. thanks

Leo is a private foundation. It doesn't disclose detailed sales figures.

[go seek]

it has been a year since ATyrn on the market...

modest sales... assume less than $1M...i.e. small potatos
expect pick up w/ time and once pregnancy indication added to HD Atryn sales, and more countries are added to the sales mix

[Lewis R Goudy]

>It's been two years since they got there hands on the product.<
That's quite tendentious--are you an old basher returned
with a new name? It has only been one year since the product
was launched and EU price negotiation on a country-by-country
basis is ongoing. For example, the UK launch was just last
November:

NeLM news service ATryn (recombinant antithrombin) launched in UK
Date published: 20/11/2007 00:00
Summary by: Yuet Wan ATryn® (recombinant antithrombin) has been launched by LEO laboratories Ltd in the UK for the prophylaxis of venous thromboembolism in surgery of patients with congenital antithrombin deficiency. It is produced from goat’s milk that has a transgene for human antithrombin and offers an alternative to treatment with plasma-derived products. ATryn is normally given in association with heparin or low molecular weight heparin and the therapeutic goal of treatment is to increase to, and maintain antithrombin activity between, 80 to 120% (0.8 – 1.2 IU/ml) for the duration of treatment. Initial treatment starts with a loading dose targeting an antithrombin activity level of 100%. This initial loading dose is based on body weight and on the pretreatment antithrombin activity level and is given as a 15 minute infusion immediately followed by initiation of the maintenance infusion. The usual loading dose in surgical patients (baseline AT activity 50%, bodyweight 75 kg) with congenital antithrombin deficiency in clinical risk situations is 20-25 IU/kg and the usual maintenance dose is 4-5 IU/kg/h.

The cost of a pack of 10 x 1750 IU vials is £17,850. Based on the usual dosing (upper dosing range) described in the SPC for a 75 kg patient, the cost of treatment is approximately £11,000 per day.

http://www.nelm.nhs.uk/en/NeLM-Area/News/492550/492768/492776/?query=leo+atryn&rank=5

[DewDiligence]

>Hi all, this is my first post.<

Actually, it’s your second post—you asked a similar question about a year ago (#msg-22086836).